相关实验视频
Updated: Jul 16, 2025

07:35
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
Published on: May 15, 2011
12.9K
对心力衰竭的基因治疗:对老年疾病的新治疗方法
Neel Vora1, Parth Patel2, Aarsh Gajjar3
1B. J. Medical College, Ahmedabad, India.
Disease-a-month : DM
|September 21, 2023
概括
基因疗法提供了一种有前途的新方法来治疗心力衰竭,这是死亡的主要原因. 虽然挑战仍然存在,但研究表明,未来在心血管疾病管理中临床应用的潜力很大.
科学领域:
- 心血管医学 心血管医学
- 分子生物学分子生物学
- 再生医学是一种再生医学.
背景情况:
- 心血管疾病 (CVD) 仍然是全球首要的死亡原因,心力衰竭影响数百万.
- 目前的心力衰竭治疗只能延缓疾病的进展,突出显示出需要新的治疗策略.
- 基因疗法为解决现有的心力衰竭护理局限性提供了潜在的突破.
结论:
- 仍然存在重大障碍,包括最终的基因选择,优化的传递系统和强大的临床前/临床试验方法.
- 尽管存在挑战,但对心力衰竭的基因治疗显示出作为未来治疗方式的鼓舞人心的潜力.
- 将基因疗法整合到标准心血管保健中的可行性和时间表需要进一步的研究和开发.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
454
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
454
Heart Failure V: Medical Management
12
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
12
Heart Failure VI: Adjunct Therapies
16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
Heart Failure Drugs: Inotropic Agents
611
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
611
Heart Failure II: Pathophysiology
14
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
14
Gene Therapy
25.5K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
25.5K

